Stephen Fawell Purchases 62,000 Shares of C4 Therapeutics

On June 24, 2026, Stephen Fawell, an insider at C4 Therapeutics, Inc. (NasdaqGS: CCCC), purchased 62,000 shares. The transaction was not part of a pre-planned trading scheme. This insider activity suggests a level of confidence in the company's prospects.

Insider Buying and Selling at C4 Therapeutics, Inc.

The buying activity on June 24, 2026, wasn't limited to Stephen Fawell. Other insiders, including Steven Hoerter, Laura Bessen, Owen Hughes, and Donna Roy Grogan, each acquired 62,000 shares on the same day. Kenneth Carl Anderson also purchased 1,070 shares on June 1, 2026, at $2.11 per share.

Other Institutional Activity in C4 Therapeutics

Several institutional investors have adjusted their holdings in C4 Therapeutics. Morgan Stanley increased its stake by 90,738 shares, bringing its total to 9,072,400 shares valued at approximately $23.86 million, marking a 1% increase. Lynx1 Capital Management LP reduced its position by 99,231 shares, holding 6,998,902 shares worth about $18.41 million, a 1.4% decrease. Vanguard Capital Management LLC opened a new position with 3,861,852 shares, valued at around $10.16 million.

C4 Therapeutics, Inc. Stock Up 10.6%

As of Saturday, shares of C4 Therapeutics traded at $4.40 on the Nasdaq. The company has a market capitalization of approximately $471 million. It operates with a high beta of 2.93, indicating significant volatility. The stock's 52-week range spans from $1.40 to $4.60, with a 50-day moving average of $3.51 and a 200-day moving average of $2.70. The company's financial health is supported by a strong current ratio of 9.00 and a quick ratio of 8.76, although it carries a debt-to-equity ratio of 24.95.

Recent Earnings

C4 Therapeutics reported revenue of $34.86 million, with a decline of 15% in revenue growth. The company's net margin stands at -297.76%, and it has a return on equity of -48.35%. The company is not currently profitable, as indicated by its negative EPS of -$1.10. C4 Therapeutics is set to announce its next earnings on August 6, 2026.

Analysts Set New Price Targets

Analysts remain bullish on C4 Therapeutics. On June 1, 2026, Evercore ISI Group maintained a 'buy' rating with a price target of $12. Barclays also maintained a 'buy' rating with a lower target of $7 on February 27, 2026. The consensus among six analysts is a 'strong buy', with a mean price target of $13.33.

About C4 Therapeutics

C4 Therapeutics, Inc., based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company. It focuses on developing innovative treatments that degrade proteins causing diseases. Its leading product, Cemsidomide, targets specific proteins in multiple myeloma. The company is also working on treatments for non-small cell lung cancer and other conditions related to inflammation and neurodegeneration. C4 collaborates with major companies like Roche and Merck.

Bottom Line

Stephen Fawell's recent purchase of 62,000 shares in C4 Therapeutics reflects insider confidence. The company, a player in the biotechnology sector, is focused on innovative therapies for serious diseases. While analysts maintain a positive outlook with a 'strong buy' consensus, investors should note that 13F filings and insider transactions are backward-looking and may not reflect current positions.